Navigation Links
Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
Date:9/1/2008

MUNICH, Germany, Sept. 2 /PRNewswire-FirstCall/ -- Data presented today at the Annual Congress of the European Society of Cardiology showed that the investigational oral Factor Xa inhibitor DU-176b reduced the incidence of venous thromboembolism (VTE) compared with dalteparin among patients undergoing elective unilateral hip replacement surgery. There was a statistically significant dose response in efficacy (P <0.01), and the observed bleeding rates were low across the groups. DU-176b is being developed solely by Daiichi Sankyo Company, Limited (TSE: 4568) and the data were presented by lead investigator Dr. Gary Raskob.

This randomized, double-blind comparative study examined the safety and efficacy of four doses of DU-176b (15, 30, 60 and 90 mg once daily) versus the low molecular weight heparin, dalteparin. The study was conducted among 903 patients in Europe and North America undergoing total hip replacement surgery.

"These findings are encouraging and we look forward to further study on this Factor Xa inhibitor," said Gary Raskob, Ph.D., Dean, College of Public Health at the University of Oklahoma Health Sciences Center. "These findings indicate DU-176b may provide a high degree of efficacy, but further study is needed."

"As the company that discovered one of the first Factor Xa small molecules (DX-9065a), we are proud to be building on our innovation in cardiovascular disease and tackling the need for better and more effective ways to prevent thrombosis," said John Alexander M.D., president, Daiichi Sankyo Pharma Development. "We expect to commence phase III studies for DU-176b, targeting patients with atrial fibrillation, before the end of 2008.

Study Result Details

VTE incidence (%) Bleeding occurrence*** (%)

Dalteparin 43.8 [35.5-52.3]# 0 [0-2.1]

DU-176b 15mg 28.2 [21.6-35.6]* 1.6 [0.3-4.5]

30mg 21.2 [15.0-28.6]** 1.8 [0.4-5.1]

60mg 15.2 [10.0-21.8]** 2.2 [0.6-5.4]

90mg 10.6 [6.2-16.6]** 2.3 [0.6-5.7]

#95% confidence interval, * p=0.005, **p<0.001, ***Major+Clinically

Relevant

About DU-176b

DU-176b is an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood. Daiichi Sankyo is developing DU-176b as a potential new treatment for the prevention of both arterial and venous thromboembolism.

About Daiichi Sankyo

A global pharmaceutical innovator, Daiichi Sankyo Co., Ltd., headed by President Takashi Shoda was established in 2005 through the merger of two leading Japanese pharmaceutical companies, Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development is cardiometabolic diseases, including therapies for thrombosis, dyslipidemia, hypertension, diabetes, and acute coronary syndromes. Equally important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit http://www.daiichisankyo.com.


'/>"/>
SOURCE Daiichi Sankyo
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
3. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... SAN DIEGO and VANCOUVER, British Columbia, March 27, ... SPHS ) (the "Company" or "Sophiris"), a clinical ... treatment of patients with urological diseases, today reported ... and key corporate highlights. Key ... in Clinical Development for Localized Prostate Cancer. During ...
(Date:3/27/2017)... , March 27, 2017 /PRNewswire/ - INVICTUS MD ... IVITF; FRA: 8IS) Invictus MD is pleased to announce ... shares for trading on the TSX Venture Exchange.  ... TSXV follows a year of significant achievements for Invictus-MD. ... successful test crops at AB Laboratories Inc. ("AB Labs"), ...
(Date:3/27/2017)... , March 27, 2017 The ... reach USD 16.0 billion by 2025, according to a ... prevalence of chronic diseases is anticipated to be responsible ... which thereby widens the scope for growth during the ... bariatric population, which is highly susceptible to chronic diseases, ...
Breaking Medicine Technology:
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently ... balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in people of ... a lot to offer to the discussion of dealing with excess skin oil. “Oily skin ... many home remedies that can help remove the oily shine while keeping the skin fresh ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
(Date:3/27/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... have the speed, agility and ability to gain site attention and engagement over ... DrugDev educational webinar will discuss how partnering with the ...
Breaking Medicine News(10 mins):